AMSTERDAM (Reuters) - Dutch biotech Crucell (Amsterdam:CRCL.AS - News) swung to a full-year loss, hit by a vaccine impairment charge and higher operating costs, but said on Monday Korean regulators back the resumption of production at its key Korean facility.
